GlassScriptPhysician profile
Lata Parvathaneni
NPI 1629396585
$7,702.86
in general payments reported to CMS, 2019-2025
38 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $1,252 · 2021: $1,949 · 2022: $1,681 · 2023: $1,287 · 2024: $1,087 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.88 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $988.24 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $823.23 | 2020-2024 | |
| Lilly USA, LLC | $817.94 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $769.38 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $760.50 | 2019-2024 | Farxiga, Breztri, Fasenra |
| Amarin Pharma, INC. | $598.91 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.13 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.28 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $283.43 | 2020-2021 | |
| Glaxosmithkline, LLC. | $239.98 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $230.53 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $213.67 | 2019-2025 | Lagevrio |
| Amgen INC. | $164.06 | 2020-2025 | Otezla, Repatha, Repatha |
| Horizon Therapeutics Plc | $136.92 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.75 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $96.38 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $90.08 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $75.00 | 2022-2023 | Quviviq |
| Esperion Therapeutics, INC. | $64.86 | 2021-2022 | |
| Abbott Laboratories | $63.16 | 2022-2025 | Freestyle Libre 3 |
| Nevro Corp. | $61.36 | 2024 | Senza |
| Eisai INC. | $50.12 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $46.94 | 2023-2024 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $41.46 | 2021 | |
| Bausch Health US, LLC | $35.35 | 2022 | |
| Daiichi Sankyo INC. | $31.47 | 2020 | |
| Allergan, INC. | $27.17 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $26.63 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $21.74 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.22 | 2023 | Rexulti |
| Genzyme Corporation | $19.55 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.34 | 2022 | |
| Phadia US INC. | $19.22 | 2022 | |
| Corcept Therapeutics | $17.15 | 2024 | Korlym |
| Medtronic USA, INC. | $16.85 | 2019 | |
| Dexcom, INC. | $16.49 | 2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $15.72 | 2023 | Edarbi |
| Teva Pharmaceuticals USA, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lata Parvathaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.